A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.

Antonio ChacraIra GantzGeraldine MendizabalLucila DurlachEdward A O'NeillZachary ZimmerShailaja SuryawanshiSamuel S EngelEseng Lai

Published in: International journal of clinical practice (2017)

In this study in subjects with T2DM and RI, relative to placebo, omarigliptin provided clinically meaningful reductions in HbA1c, had a similar incidence of symptomatic hypoglycaemia and was generally well tolerated.

Keyphrases

double blind
phase iii
placebo controlled
clinical trial
study protocol
phase ii
open label
type diabetes
randomized controlled trial
risk factors
metabolic syndrome
skeletal muscle